Multiple Pulmonary Metastases of Recurrent Giant Cell Tumor of Bone with Expression of VEGFR-2 Successfully Controlled by Denosumab and Apatinib: A Case Report and Literature Review

References

• Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, Phase 2 study. Lancet Oncol. 2010;11(3):275–280. doi:10.1016/S1470-2045(10)70010-320149736
   PubMed Web of Science ®Google Scholar
• Mendenhall WM, Zlotecki RA, Scarborough MT, Gibbs CP, Mendenhall NP. Giant cell tumor of bone. Am J Clin Oncol. 2006;29(1):96–99. doi:10.1097/01.coc.0000195089.11620.b716462511
   PubMed Web of Science ®Google Scholar
• Wang J, Liu X, Yang Y, et al. Pulmonary metastasis of giant cell tumour: a retrospective study of three hundred and ten cases. Int Orthop. 2021;45(3):769–778. doi:10.1007/s00264-020-04907-033427899
   PubMed Web of Science ®Google Scholar
• Bertoni F, Present D, Sudanese A, Baldini N, Bacchini P, Campanacci M. Giant-cell tumor of bone with pulmonary metastases. Six case reports and a review of the literature. Clin Orthop Relat Res. 1988;237:275–285.
   Google Scholar
• Chawla S, Blay JY, Rutkowski P, et al. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019;20(12):1719–1729. doi:10.1016/S1470-2045(19)30663-131704134
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled Phase III Trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34(13):1448–1454. doi:10.1200/JCO.2015.63.599526884585
   PubMed Web of Science ®Google Scholar
• Zhu B, Li J, Xie Q, Diao L, Gai L, Yang W. Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: an observational study. Cancer Biol Ther. 2018;19(3):198–204. doi:10.1080/15384047.2017.141627529261005
   PubMed Web of Science ®Google Scholar
• Li J, Zhao X, Chen L, et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer. 2010;10:529. doi:10.1186/1471-2407-10-52920923544
   PubMed Web of Science ®Google Scholar
• Xie L, Guo W, Wang Y, Yan T, Ji T, Xu J. Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China. BMC Cancer. 2018;18(1):396. doi:10.1186/s12885-018-4303-z29625604
   PubMed Web of Science ®Google Scholar
• Wang Y, Min L, Zhou Y, et al. The efficacy and safety of apatinib in metastatic alveolar soft part sarcoma: a case series of six patients in one institution. Cancer Manag Res. 2019;11:3583–3591. doi:10.2147/CMAR.S19842931118781
   PubMed Web of Science ®Google Scholar
• Yang Y, Huang Z, Niu X, Xu H, Li Y, Liu W. Clinical characteristics and risk factors analysis of lung metastasis of benign giant cell tumor of bone. J Bone Oncol. 2017;7:23–28. doi:10.1016/j.jbo.2017.04.00128443231
   PubMed Web of Science ®Google Scholar
• Biermann JS, Chow W, Reed DR, et al. NCCN guidelines insights: bone cancer, version 2.2017. J Natl Compr Canc Netw. 2017;15(2):155–167. doi:10.6004/jnccn.2017.001728188186
   PubMed Web of Science ®Google Scholar
• Luo Y, Tang F, Wang Y, et al. Safety and efficacy of denosumab in the treatment of pulmonary metastatic giant cell tumor of bone. Cancer Manag Res. 2018;10:1901–1906. doi:10.2147/CMAR.S16187130013396
   PubMedGoogle Scholar
• Chawla S, Henshaw R, Seeger L, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013;14(9):901–908. doi:10.1016/S1470-2045(13)70277-823867211
   PubMed Web of Science ®Google Scholar
• López-Pousa A, Martín Broto J, Garrido T, Vázquez J. Giant cell tumour of bone: new treatments in development. Clin Transl Oncology. 2015;17(6):419–430. doi:10.1007/s12094-014-1268-5
   PubMed Web of Science ®Google Scholar
• Broehm CJ, Garbrecht EL, Wood J, Bocklage T. Two cases of sarcoma arising in giant cell tumor of bone treated with denosumab. Case Rep Med. 2015;2015:767198. doi:10.1155/2015/76719826798348
   PubMedGoogle Scholar
• Tsukamoto S, Righi A, Vanel D, Honoki K, Donati DM, Errani C. Development of high-grade osteosarcoma in a patient with recurrent giant cell tumor of the ischium while receiving treatment with denosumab. Jpn J Clin Oncol. 2017;47(11):1090–1096. doi:10.1093/jjco/hyx11229048579
   PubMed Web of Science ®Google Scholar
• Aponte-Tinao LA, Piuzzi NS, Roitman P, Farfalli GL, High-grade Sarcoma A. Arising in a patient with recurrent benign giant cell tumor of the proximal tibia while receiving treatment with denosumab. Clin Orthop Relat Res. 2015;473(9):3050–3055. doi:10.1007/s11999-015-4249-225758379
   PubMed Web of Science ®Google Scholar
• Wang G, Jiang S, Li Z, Dong Y. Denosumab and Sunitinib in the treatment of giant-cell tumor of bone with pulmonary and bone metastases in an adolescent: a case report. Medicine (Baltimore). 2019;98(46):e17778. doi:10.1097/MD.000000000001777831725619
   PubMed Web of Science ®Google Scholar
• Gossai N, Hilgers MV, Polgreen LE, Greengard EG. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone. Pediatr Blood Cancer. 2015;62(6):1078–1080. doi:10.1002/pbc.2539325556556
   PubMed Web of Science ®Google Scholar
• Matcuk GR Jr, Patel DB, Schein AJ, White EA, Menendez LR. Giant cell tumor: rapid recurrence after cessation of long-term denosumab therapy. Skeletal Radiol. 2015;44(7):1027–1031. doi:10.1007/s00256-015-2117-525712768
   PubMed Web of Science ®Google Scholar
• English WR, Lunt SJ, Fisher M, et al. Differential expression of VEGFA isoforms regulates metastasis and response to anti-VEGFA therapy in sarcoma. Cancer Res. 2017;77(10):2633–2646. doi:10.1158/0008-5472.CAN-16-025528377452
   PubMed Web of Science ®Google Scholar
• Zhang J, Dong J, Yang Z, et al. Expression of ezrin, CD44, and VEGF in giant cell tumor of bone and its significance. World J Surg Oncol. 2015;13:168. doi:10.1186/s12957-015-0579-525929323
   PubMed Web of Science ®Google Scholar
• Shibuya M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem. 2013;153(1):13–19. doi:10.1093/jb/mvs13623172303
   PubMed Web of Science ®Google Scholar
• Li J, Zhou J, Liu Y, Sun X, Song W. Comprehensive treatment for multicentric giant cell tumors of the pelvis and spine using apatinib: a case report and literature review. J Cancer Res Ther. 2020;16(5):1020–1026. doi:10.4103/jcrt.JCRT_892_1933004743
   PubMed Web of Science ®Google Scholar